ECSP19044484A - Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x - Google Patents
Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación xInfo
- Publication number
- ECSP19044484A ECSP19044484A ECSENADI201944484A ECDI201944484A ECSP19044484A EC SP19044484 A ECSP19044484 A EC SP19044484A EC SENADI201944484 A ECSENADI201944484 A EC SENADI201944484A EC DI201944484 A ECDI201944484 A EC DI201944484A EC SP19044484 A ECSP19044484 A EC SP19044484A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- fxz
- fixa
- coagulation factor
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos que se unen selectivamente a formas específicas de factores de coagulación, en particular, anticuerpos que se unen específicamente al factor IX activado (FIXa) en donde el anticuerpo anti-FIXa o una porción de unión al antígeno del mismo se une preferentemente a FIXa en presencia de FIXa y zimógeno de factor IX (FIXz), y anticuerpos que se unen específicamente al zimógeno de factor X (FXz) en donde el anticuerpo anti-FXz o la porción de unión al antígeno del mismo se une preferentemente a FXz en presencia de FXz y factor X activado (FXa). También se proporcionan moléculas biespecíficas (por ejemplo, anticuerpos) que comprenden, por ejemplo, un anticuerpo anti-FIXa o una porción de unión al antígeno del mismo y/o un anticuerpo anti-FXz o una porción de unión al antígeno del mismo. La descripción también proporciona composiciones que codifican los anticuerpos descritos y moléculas, vectores, células, composiciones farmacéuticas y de diagnóstico, kits, métodos de fabricación, métodos de uso e inmunoconjugados biespecíficos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662425921P | 2016-11-23 | 2016-11-23 | |
US201762452809P | 2017-01-31 | 2017-01-31 | |
US201762529805P | 2017-07-07 | 2017-07-07 | |
US201762587284P | 2017-11-16 | 2017-11-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP19044484A true ECSP19044484A (es) | 2019-08-30 |
Family
ID=60766147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI201944484A ECSP19044484A (es) | 2016-11-23 | 2019-06-21 | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x |
Country Status (21)
Country | Link |
---|---|
US (1) | US20230192896A1 (es) |
EP (1) | EP3545002A2 (es) |
JP (2) | JP7227146B2 (es) |
KR (1) | KR20190080949A (es) |
CN (1) | CN110662770A (es) |
AU (1) | AU2017363309A1 (es) |
BR (1) | BR112019010349A2 (es) |
CA (1) | CA3044574A1 (es) |
CL (1) | CL2019001372A1 (es) |
CO (1) | CO2019006500A2 (es) |
CR (1) | CR20190297A (es) |
DO (1) | DOP2019000127A (es) |
EC (1) | ECSP19044484A (es) |
IL (1) | IL266749A (es) |
MA (1) | MA46893A (es) |
MX (1) | MX2019005772A (es) |
PE (1) | PE20200012A1 (es) |
PH (1) | PH12019501126A1 (es) |
TN (1) | TN2019000164A1 (es) |
TW (1) | TW201819417A (es) |
WO (1) | WO2018098363A2 (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
MA40861A (fr) * | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Anticorps anti-glycoprotéines iib/iiia |
GB201709970D0 (en) | 2017-06-22 | 2017-08-09 | Kymab Ltd | Bispecific antigen-binding molecules |
CN111094352A (zh) | 2017-08-25 | 2020-05-01 | 戊瑞治疗有限公司 | B7-h4抗体及其使用方法 |
EP3710486A1 (en) | 2017-11-15 | 2020-09-23 | Novo Nordisk A/S | Factor x binders enhancing fx activation |
WO2019169212A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
FR3082427B1 (fr) * | 2018-06-14 | 2020-09-25 | Lab Francais Du Fractionnement | Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x |
CN112654363A (zh) * | 2018-07-09 | 2021-04-13 | 瑟罗泽恩公司 | 组织特异性wnt信号增强分子和其用途 |
US11220554B2 (en) | 2018-09-07 | 2022-01-11 | Novo Nordisk A/S | Procoagulant antibodies |
AU2019313550B2 (en) | 2018-08-01 | 2024-02-08 | Novo Nordisk A/S | Improved procoagulant antibodies |
US20220056124A1 (en) * | 2018-09-05 | 2022-02-24 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies against endotrophin and the use thereof |
TW202039583A (zh) * | 2018-12-07 | 2020-11-01 | 瑞士商巴克斯歐塔有限公司 | 結合因子IXa及因子X的蛋白分子 |
WO2020115283A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020114615A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Bispecific antibodies binding factor ixa and factor x |
WO2020114614A1 (en) * | 2018-12-07 | 2020-06-11 | Baxalta GmbH | Proteinaceous molecules binding factor ixa and factor x |
BR112021011393A2 (pt) * | 2018-12-13 | 2021-08-31 | Surface Oncology, Inc. | Anticorpos anti-il-27 e usos dos mesmos |
BR112021012065A2 (pt) | 2018-12-21 | 2021-12-07 | Kymab Ltd | Anticorpo biespecífico que se liga a fixa e fx e catalisa a ativação de fx mediada por fixa; método; anticorpo anti-fixa; anticorpo anti-fx; ácido nucleico isolado; célula hospedeira in vitro; população de células hospedeiras in vitro; kit para produção de um anticorpo biespecífico; método de produção de um anticorpo biespecífico; composição; método para controlar o sangramento em um paciente com hemofilia a; uso de um anticorpo biespecífico; método, composição para uso ou uso; e método para reduzir o desenvolvimento de anticorpos antifármacos inibidores em um paciente com hemofilia a em tratamento com um polipeptídeo que substitui a atividade de fviiia |
JP2023512089A (ja) * | 2020-01-30 | 2023-03-23 | ノヴォ ノルディスク アー/エス | 二重特異性第viii因子模倣抗体 |
JP2023106635A (ja) | 2020-04-17 | 2023-08-02 | 中外製薬株式会社 | 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法 |
US11919944B2 (en) | 2020-05-11 | 2024-03-05 | Augmenta Biosciences, Inc. | Antibodies for SARS-CoV-2 and uses thereof |
BR112022025295A2 (pt) | 2020-06-12 | 2023-04-25 | Nkarta Inc | Células natural killer modificadas geneticamente para imunoterapia do câncer direcionada a cd70 |
CA3214653A1 (en) * | 2021-04-09 | 2022-10-13 | Heyue Zhou | Antigen binding proteins that bind ror1 |
WO2023111018A1 (en) * | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Antibodies against coagulation factor x and uses thereof |
WO2023219922A1 (en) * | 2022-05-12 | 2023-11-16 | Merck Sharp & Dohme Llc | Anti-integrin antibodies and uses thereof |
WO2024050356A2 (en) * | 2022-08-29 | 2024-03-07 | Invivyd, Inc. | Sars-cov2 antibodies and uses thereof |
WO2024107728A1 (en) * | 2022-11-15 | 2024-05-23 | Calico Life Sciences Llc | Anti-papp-a antibodies and methods of use thereof |
WO2024108158A1 (en) * | 2022-11-18 | 2024-05-23 | Byomass Inc. | Anti-activin a/b antibodies and uses thereof |
CN116589588B (zh) * | 2023-04-14 | 2023-12-22 | 北京基科晟斯医药科技有限公司 | 结合凝血因子x的抗体 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
DE3587814T2 (de) | 1985-03-30 | 1994-11-10 | Marc Ballivet | Verfahren zum erhalten von dns, rns, peptiden, polypeptiden oder proteinen durch dns-rekombinant-verfahren. |
US4770999A (en) | 1985-04-22 | 1988-09-13 | Genetics Institute, Inc. | High yield production of active Factor IX |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
DE3600905A1 (de) | 1986-01-15 | 1987-07-16 | Ant Nachrichtentech | Verfahren zum dekodieren von binaersignalen sowie viterbi-dekoder und anwendungen |
US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5763192A (en) | 1986-11-20 | 1998-06-09 | Ixsys, Incorporated | Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990014443A1 (en) | 1989-05-16 | 1990-11-29 | Huse William D | Co-expression of heteromeric receptors |
CA2016841C (en) | 1989-05-16 | 1999-09-21 | William D. Huse | A method for producing polymers having a preselected activity |
CA2016842A1 (en) | 1989-05-16 | 1990-11-16 | Richard A. Lerner | Method for tapping the immunological repertoire |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
JP4157160B2 (ja) | 1991-12-13 | 2008-09-24 | ゾーマ テクノロジー リミテッド | 改変抗体可変領域の調製のための方法 |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
EP0640094A1 (en) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5681702A (en) | 1994-08-30 | 1997-10-28 | Chiron Corporation | Reduction of nonspecific hybridization by using novel base-pairing schemes |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6706484B1 (en) | 1995-08-18 | 2004-03-16 | Morphosys Ag | Protein/(poly)peptide libraries |
JP4436457B2 (ja) | 1995-08-18 | 2010-03-24 | モルフォシス アイピー ゲーエムベーハー | 蛋白質/(ポリ)ペプチドライブラリー |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5714352A (en) | 1996-03-20 | 1998-02-03 | Xenotech Incorporated | Directed switch-mediated DNA recombination |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
ES2694002T3 (es) | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
CA2339889C (en) | 1999-07-02 | 2012-01-31 | Morphosys Ag | Identification of specific binding partners binding to (poly)peptides encoded by genomic dna fragments or ests |
AT411997B (de) * | 1999-09-14 | 2004-08-26 | Baxter Ag | Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate |
ES2269366T3 (es) | 2000-02-11 | 2007-04-01 | Merck Patent Gmbh | Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos. |
AU2001247616B2 (en) | 2000-04-11 | 2007-06-14 | Genentech, Inc. | Multivalent antibodies and uses therefor |
US6725230B2 (en) | 2000-07-18 | 2004-04-20 | Aegis Analytical Corporation | System, method and computer program for assembling process data of multi-database origins using a hierarchical display |
US7117096B2 (en) | 2001-04-17 | 2006-10-03 | Abmaxis, Inc. | Structure-based selection and affinity maturation of antibody library |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
WO2003074679A2 (en) | 2002-03-01 | 2003-09-12 | Xencor | Antibody optimization |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
EP1916001B1 (en) * | 2002-03-04 | 2011-05-25 | Imclone LLC | Human antibodies specific to KDR and uses thereof |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
ATE536188T1 (de) | 2002-08-14 | 2011-12-15 | Macrogenics Inc | Fcgammariib-spezifische antikörper und verfahren zur verwendung davon |
DK2345671T3 (en) | 2002-09-27 | 2016-02-15 | Xencor Inc | Optimized Fc variants and methods for their formation |
AU2003286467B2 (en) | 2002-10-15 | 2009-10-01 | Abbvie Biotherapeutics Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
CN1795009B (zh) | 2002-11-07 | 2014-07-09 | 伊谬诺金公司 | 抗-cd33抗体及其用途 |
WO2004063351A2 (en) | 2003-01-09 | 2004-07-29 | Macrogenics, Inc. | IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME |
US7297336B2 (en) * | 2003-09-12 | 2007-11-20 | Baxter International Inc. | Factor IXa specific antibodies displaying factor VIIIa like activity |
US8101720B2 (en) | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
AU2003271174A1 (en) | 2003-10-10 | 2005-04-27 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
JP5490734B2 (ja) * | 2003-10-10 | 2014-05-14 | 中外製薬株式会社 | 機能蛋白質を代替する二種特異性抗体 |
GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
BRPI0506771A (pt) | 2004-01-12 | 2007-05-22 | Applied Molecular Evolution | anticorpo, e, composição farmacêutica |
US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
WO2005092925A2 (en) | 2004-03-24 | 2005-10-06 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
CA2573192C (en) | 2004-08-04 | 2013-09-10 | Applied Molecular Evolution Inc. | Variant fc regions |
AU2005279347A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
EP3623473A1 (en) | 2005-03-31 | 2020-03-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
EP2109622B1 (en) * | 2007-01-03 | 2016-11-09 | Morphotek, Inc. | High affinity antibodies that neutralize staphylcoccus enterotoxin b |
US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8691730B2 (en) | 2007-09-14 | 2014-04-08 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
EP2287174B8 (en) | 2008-01-18 | 2016-12-07 | Bio-Rad Laboratories, Inc. | Enhanced purification of antibody fragments by apatite chromatography |
MX2011010159A (es) | 2009-04-02 | 2011-10-17 | Roche Glycart Ag | Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla. |
JP5616428B2 (ja) | 2009-04-07 | 2014-10-29 | ロシュ グリクアート アクチェンゲゼルシャフト | 三価の二重特異性抗体 |
CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
EP2435473B1 (en) | 2009-05-27 | 2013-10-02 | F.Hoffmann-La Roche Ag | Tri- or tetraspecific antibodies |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
US8703132B2 (en) | 2009-06-18 | 2014-04-22 | Hoffmann-La Roche, Inc. | Bispecific, tetravalent antigen binding proteins |
WO2011034605A2 (en) | 2009-09-16 | 2011-03-24 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
CN105734678B (zh) | 2010-07-16 | 2019-11-05 | 阿迪马布有限责任公司 | 合成多核苷酸文库 |
MX355060B (es) * | 2010-11-17 | 2018-04-03 | Chugai Pharmaceutical Co Ltd | Molecula multiespecifica de union a antigeno que tiene funcion alternativa a la funcion del factor viii de coagulacion sanguinea. |
KR102106002B1 (ko) | 2011-10-11 | 2020-05-07 | 제넨테크, 인크. | 이중특이적 항체의 개선된 어셈블리 |
RU2644341C2 (ru) | 2012-02-10 | 2018-02-08 | Дженентек, Инк. | Одноцепочечные антитела и другие гетеромультимеры |
AU2016248817A1 (en) * | 2015-04-17 | 2017-08-17 | F. Hoffmann-La Roche Ag | Combination therapy with coagulation factors and multispecific antibodies |
-
2017
- 2017-11-22 CR CR20190297A patent/CR20190297A/es unknown
- 2017-11-22 AU AU2017363309A patent/AU2017363309A1/en not_active Abandoned
- 2017-11-22 CA CA3044574A patent/CA3044574A1/en not_active Abandoned
- 2017-11-22 PE PE2019001058A patent/PE20200012A1/es unknown
- 2017-11-22 JP JP2019547608A patent/JP7227146B2/ja active Active
- 2017-11-22 CN CN201780084392.6A patent/CN110662770A/zh active Pending
- 2017-11-22 TN TNP/2019/000164A patent/TN2019000164A1/en unknown
- 2017-11-22 BR BR112019010349A patent/BR112019010349A2/pt not_active Application Discontinuation
- 2017-11-22 US US16/462,878 patent/US20230192896A1/en active Pending
- 2017-11-22 MA MA046893A patent/MA46893A/fr unknown
- 2017-11-22 MX MX2019005772A patent/MX2019005772A/es unknown
- 2017-11-22 WO PCT/US2017/063135 patent/WO2018098363A2/en unknown
- 2017-11-22 KR KR1020197017712A patent/KR20190080949A/ko not_active Application Discontinuation
- 2017-11-22 EP EP17817962.8A patent/EP3545002A2/en active Pending
- 2017-11-23 TW TW106140758A patent/TW201819417A/zh unknown
-
2019
- 2019-05-20 IL IL266749A patent/IL266749A/en unknown
- 2019-05-20 CL CL2019001372A patent/CL2019001372A1/es unknown
- 2019-05-21 PH PH12019501126A patent/PH12019501126A1/en unknown
- 2019-05-21 DO DO2019000127A patent/DOP2019000127A/es unknown
- 2019-06-20 CO CONC2019/0006500A patent/CO2019006500A2/es unknown
- 2019-06-21 EC ECSENADI201944484A patent/ECSP19044484A/es unknown
-
2023
- 2023-02-08 JP JP2023017261A patent/JP2023058589A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
TN2019000164A1 (en) | 2020-10-05 |
JP2023058589A (ja) | 2023-04-25 |
AU2017363309A1 (en) | 2019-07-11 |
CR20190297A (es) | 2019-11-01 |
CN110662770A (zh) | 2020-01-07 |
PH12019501126A1 (en) | 2019-08-19 |
WO2018098363A2 (en) | 2018-05-31 |
WO2018098363A3 (en) | 2018-09-20 |
US20230192896A1 (en) | 2023-06-22 |
KR20190080949A (ko) | 2019-07-08 |
JP7227146B2 (ja) | 2023-02-21 |
CA3044574A1 (en) | 2018-05-31 |
CO2019006500A2 (es) | 2019-06-28 |
MA46893A (fr) | 2019-10-02 |
IL266749A (en) | 2019-07-31 |
DOP2019000127A (es) | 2019-10-15 |
CL2019001372A1 (es) | 2019-11-04 |
TW201819417A (zh) | 2018-06-01 |
EP3545002A2 (en) | 2019-10-02 |
BR112019010349A2 (pt) | 2019-10-08 |
JP2019535325A (ja) | 2019-12-12 |
PE20200012A1 (es) | 2020-01-06 |
MX2019005772A (es) | 2019-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP19044484A (es) | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x | |
CL2018002490A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866) | |
CL2018000502A1 (es) | Anticuerpos biespecíficos para pd1 y tim3 útiles como inmunomoduladores o en el tratamiento del cáncer. | |
ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
CO2018000887A2 (es) | Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3 | |
PH12016501212A1 (en) | Human anti-il-33 neutralizing monoclonal antibody | |
EA201891983A1 (ru) | Комбинированная терапия антителами к cd73 | |
UY36974A (es) | Anticuerpos anti-il1rap, moléculas de unión a antígenos biespecíficas que se unen a il1rap y cd3, y usos de estas | |
CO2019008461A2 (es) | Anticuerpos procoagulantes | |
ECSP19005417A (es) | Anticuerpos específicos para la tau hiperfosforilada y sus métodos de uso | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
UY37683A (es) | Anticuerpo monoclonal anti-pd-l1 monoclonal | |
CO2017004753A2 (es) | Anticuerpos que se unen a ccr6 | |
CL2021000186A1 (es) | Anticuerpos procoagulantes mejorados | |
CO2019010164A2 (es) | Anticuerpos que se unen a steap-1 | |
AR110680A1 (es) | Anticuerpos biespecíficos que se unen al factor de coagulación ix y al factor de coagulación x | |
EA201891196A1 (ru) | Cgrp-антитела и их применение | |
ECSP20024551A (es) | ANTICUERPO MONOCLONAL PARA IL-5Ra | |
EA201991246A1 (ru) | Моно- и биспецифические антитела, связывающиеся с фактором коагуляции ix и фактором коагуляции x | |
AR114539A1 (es) | Anticuerpos procoagulantes mejorados | |
CR20190012A (es) | Anticuerpos específicos para la tauy hiperfosforilada y sus métodos de uso |